Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.80 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.80 |
| ▸ | MAPT | P10636 | 3/20 | 0.80 |
| ▸ | LMNA | P02545 | 2/20 | 0.80 |
| ▸ | TSHR | P16473 | 2/20 | 0.80 |
| ▸ | BLM | P54132 | 2/20 | 0.80 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.80 |
| ▸ | MEN1 | O00255 | 2/20 | 0.80 |
| ▸ | MPO | P05164 | 1/20 | 0.80 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.80 |
| ▸ | HTR1A | P08908 | 2/20 | 0.67 |
| ▸ | HTR2A | P28223 | 2/20 | 0.67 |
| ▸ | HTR2C | P28335 | 2/20 | 0.67 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.67 |
| ▸ | HTR7 | P34969 | 2/20 | 0.67 |
| ▸ | HTR2B | P41595 | 2/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.67 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.67 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.67 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dl-Tryptophan SCHEMBL27153674 | 1.00 | KMT2A (0.80) | KMT2AKDM4EMAPTLMNATSHR | |
| D-Tryptophan SCHEMBL10359011 | 1.00 | KMT2A (0.80) | KMT2AKDM4EMAPTLMNATSHR | |
| D-Tryptophan SCHEMBL10359012 | 1.00 | KMT2A (0.80) | KMT2AKDM4EMAPTLMNATSHR | |
| Tryptophan SCHEMBL15168746 | 1.00 | KMT2A (0.80) | KMT2AKDM4EMAPTLMNATSHR | |
| Tryptophan SCHEMBL6032938 | 1.00 | KMT2A (0.80) | KMT2AKDM4EMAPTLMNATSHR | |
| Tryptophan SCHEMBL243574 | 1.00 | KMT2A (0.80) | KMT2AKDM4EMAPTLMNATSHR | |
| Dl-Tryptophan SCHEMBL152717 | 0.99 | KMT2A (0.78) | KMT2AKDM4EMAPTLMNATSHR | |
| Tryptophan SCHEMBL325026 | 0.99 | KMT2A (0.78) | KMT2AKDM4EMAPTLMNATSHR | |
| Dl-Tryptophan SCHEMBL27561249 | 0.99 | KMT2A (0.78) | KMT2AKDM4EMAPTLMNATSHR | |
| Tryptophan SCHEMBL9449482 | 0.95 | KDM4E (0.73) | KMT2AKDM4EMAPTLMNATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 176 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023083323-A1 | A PEPTIDE AND THE SELECTION METHOD THEREOF | THE HONG KONG UNIVERSITY OF SCIENCE AND TECHNOLOGY (CN) | 2023-05-19 | — | — | WO | claimed |
| CN-115327129-A | Application of plasma molecular marker kynurenine in early heart failure detection | 上海交通大学医学院附属上海儿童医学中心 | 2022-11-11 | — | — | CN | claimed |
| EP-3177669-B1 | AMPHIPHILIC BLOCKCOPOLYMERS COMPRISING REDUCTION SENSITIVE BIODEGRADABLE POLYESTERAMIDES | DSM IP ASSETS BV (NL) | 2021-03-17 | — | — | EP | claimed |
| EP-3177669-A1 | AMPHIPHILIC BLOCKCOPOLYMERS COMPRISING REDUCTION SENSITIVE BIODEGRADABLE POLYESTERAMIDES | DSM IP Assets B.V. (NL) | 2017-06-14 | — | — | EP | claimed |
| WO-2016020547-A1 | AMPHIPHILIC BLOCKCOPOLYMERS COMPRISING REDUCTION SENSITIVE BIODEGRADABLE POLYESTERAMIDES | DSM IP ASSETS B.V. (NL) | 2016-02-11 | — | — | WO | claimed |
| US-20100120721-A1 | SUBSTITUTED PIPERIDINOPHENYL OXAZOLIDINONES | WOCKHARDT RESEARCH CENTRE (IN) | 2010-05-13 | — | — | US | claimed |
| US-6774213-B1 | CONTAIN ONE MUTATIONS IN THE MAW (MAKES ATP WORK) MOTIF; MUTANTS RELY ON REPLACEMENT OF WILDTYPE AMINO ACID RESIDUES TO ALTER THE THREE-DIMENSIONAL STRUCTURE OF THE MAW MOTIF AND TO CHANGE THE PROTEIN'S DNA-BINDING PROPERTIES | Roca, Alberto I. | 2004-08-10 | — | — | US | claimed |
| US-20030012817-A1 | Oral drug delivery compositions and methods | EMISPHERE TECHNOLOGIES, INC. | 2003-01-16 | — | — | US | claimed |
| US-20020052422-A1 | Oral drug delivery compositions and methods | EMISPHERE TECHNOLOGIES, INC. | 2002-05-02 | — | — | US | claimed |
| US-5935601-A | Modified amino acids for drug delivery | EMISPHERE TECHNOLOGIES, INC. (US) | 1999-08-10 | — | — | US | claimed |
| EP-0758843-A4 | MODIFIED AMINO ACIDS FOR DRUG DELIVERY | EMISPHERE TECH INC (US) | 1998-05-20 | — | — | EP | claimed |
| US-5686422-A | Synthetic inhibitors of mammalian collagenase | RESEARCH CORPORATION TECHNOLOGIES, INC. (US) | 1997-11-11 | — | — | US | claimed |
| US-5629020-A | Modified amino acids for drug delivery | EMISPHERE TECHNOLOGIES, INC. (US) | 1997-05-13 | — | — | US | claimed |
| EP-0758843-A1 | MODIFIED AMINO ACIDS FOR DRUG DELIVERY | Emisphere Technologies, Inc. (US) | 1997-02-26 | — | — | EP | claimed |
| EP-0696208-A4 | ORAL DRUG DELIVERY COMPOSITIONS AND METHODS | EMISPHERE TECH INC (US) | 1997-01-29 | — | — | EP | claimed |
| EP-0696208-A1 | ORAL DRUG DELIVERY COMPOSITIONS AND METHODS | Emisphere Technologies, Inc. (US) | 1996-02-14 | — | — | EP | claimed |
| WO-1995028838-A1 | MODIFIED AMINO ACIDS FOR DRUG DELIVERY | EMISPHERE TECHNOLOGIES, INC. (US) | 1995-11-02 | — | — | WO | claimed |
| WO-1994023767-A1 | ORAL DRUG DELIVERY COMPOSITIONS AND METHODS | EMISPHERE TECHNOLOGIES, INC. (US) | 1994-10-27 | — | — | WO | claimed |
| EP-0313380-B1 | Synthetic melanin aggregates | ADVANCED POLYMER SYSTEMS INC (US) | 1993-12-29 | — | — | EP | claimed |
| EP-0290269-A2 | Immunoassay methods and reagents and methods for producing the latter | CYBERFLUOR INC. (CA) | 1988-11-09 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030012817-A1 | Oral drug delivery compositions and methods | PTMS, ADM2, DNPEP | KMT2A 1224/4885KDM4E 688/4885MAPT 3281/4885 |
| US-20020052422-A1 | Oral drug delivery compositions and methods | ADM2, PTMS, DNPEP | KMT2A 887/4885KDM4E 303/4885MAPT 2217/4885 |
| US-20100120721-A1 | SUBSTITUTED PIPERIDINOPHENYL OXAZOLIDINONES | CYP2C19, ALPI, CYP3A7 | KMT2A 4463/4885KDM4E 3606/4885MAPT 1837/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.